Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 161-170 of 969 for hematology

Edit search filters
  1. Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

    Rochester, MN

  2. A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  3. Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

    Scottsdale/Phoenix, AZ

  4. A Study to Evaluate the Long-Term Safety and Effectiveness of Caplacizumab for Patients who Completed Study ALX0681-C301

    Rochester, MN

  5. CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies

    Rochester, MN

  6. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration

    Eau Claire, WI, Rochester, MN, Scottsdale/Phoenix, AZ

  7. Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

  8. A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

    Rochester, MN

  9. A Study of Using Mesenchymal Stem Cells Developed from the Patients Own Fat Tissue for Reducing Hemodialysis Arteriovenous Fistula Failure

    Rochester, MN

  10. Individualized Temozolomide in Treating Patients with Stage IV Melanoma that Cannot be Removed by Surgery

    Rochester, MN

.

Mayo Clinic Footer